Diabetic Neuropathic Pain Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies by DelveInsight |Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Neuropathic Pain pipeline constitutes 10+ key companies continuously working towards developing 12+ Diabetic Neuropathic Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Neuropathic Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Diabetic Neuropathic Pain Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Neuropathic Pain Market.

Some of the key takeaways from the Diabetic Neuropathic Pain Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Diabetic Neuropathic Pain treatment therapies with a considerable amount of success over the years.

*
Diabetic Neuropathic Pain companies working in the treatment market are Rigshospitalet, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eli Lilly and Company, GlaxoSmithKline, Apurano Pharmaceuticals, and others, are developing therapies for the Diabetic Neuropathic Pain treatment

*
Emerging Diabetic Neuropathic Pain therapies in the different phases of clinical trials are- Incobotulinumtoxin-A 100 UNIT Injection, pregabalin sustained-release tablets, RTA 901, LX9211, JMKX000623, LY3556050, GSK3858279, Adezunap (AP707), and others are expected to have a significant impact on the Diabetic Neuropathic Pain market in the coming years.

*
In May 2024, Medidata, a brand under Dassault Systemes and a leading provider of clinical trial solutions for the life sciences sector, has been chosen by Lexicon Pharmaceuticals, Inc. to support the advancement of the PROGRESS Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP). LX9211 holds promise as a potential breakthrough, being considered as the first new non-opioid drug for neuropathic pain to receive approval in more than twenty years. Medidata's expertise will assist Lexicon in expediting patient enrollment and facilitating clinical trials for LX9211, a novel AAK1 inhibitor. This collaboration aims to enhance the patient experience and address the significant unmet need for effective therapies targeting chronic neuropathic pain.

*
In January 2024, Neuralace Medical, Inc., a pioneer in pain management technology, has proudly revealed the FDA clearance of its revolutionary product, Axon Therapy (mPNS), designed for the treatment of chronic Painful Diabetic Neuropathy (PDN). This significant milestone represents the inaugural FDA clearance of a non-invasive magnetic peripheral nerve stimulation (mPNS) treatment for PDN, providing fresh optimism for the millions enduring this incapacitating ailment.

*
In December 2023, Vertex Pharmaceuticals has announced positive results from a Phase II dose-ranging trial of VX-548 in individuals suffering from painful diabetic peripheral neuropathy (DPN). The trial, registered under NCT05660538, demonstrated that all dose groups treated with VX-548 experienced a significant and clinically meaningful reduction in pain, as measured by the Numeric Pain Rating Scale (NPRS) at week 12. VX-548, an investigational oral selective inhibitor targeting NaV1.8, exhibited good tolerability across all tested doses in the study, with most adverse events (AEs) reported as mild to moderate. Importantly, there were no serious adverse events (SAEs) associated with VX-548.

Diabetic Neuropathic Pain Overview

Diabetic neuropathic pain (DNP) is a type of chronic pain that occurs as a complication of diabetes mellitus. It is caused by damage to the nerves as a result of prolonged high levels of blood sugar (glucose) associated with diabetes.

Get a Free Sample PDF Report to know more about Diabetic Neuropathic Pain Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight [https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Diabetic Neuropathic Pain Drugs Under Different Phases of Clinical Development Include:

*
Incobotulinumtoxin-A 100 UNIT Injection: Rigshospitalet, Denmark

*
pregabalin sustained-release tablets: CSPC Ouyi Pharmaceutical Co., Ltd.

*
RTA 901: Reata

*
LX9211: Lexicon Pharmaceuticals

*
JMKX000623: Jemincare

*
LY3556050: Eli Lilly and Company

*
GSK3858279: GlaxoSmithKline

*
Adezunap (AP707): Apurano Pharmaceuticals

Diabetic Neuropathic Pain Route of Administration

Diabetic Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Intravenous

*
Subcutaneous

*
Parenteral

*
Topical

Diabetic Neuropathic Pain Molecule Type

Diabetic Neuropathic Pain Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Diabetic Neuropathic Pain Pipeline Therapeutics Assessment

*
Diabetic Neuropathic Pain Assessment by Product Type

*
Diabetic Neuropathic Pain By Stage and Product Type

*
Diabetic Neuropathic Pain Assessment by Route of Administration

*
Diabetic Neuropathic Pain By Stage and Route of Administration

*
Diabetic Neuropathic Pain Assessment by Molecule Type

*
Diabetic Neuropathic Pain by Stage and Molecule Type

DelveInsight's Diabetic Neuropathic Pain Report covers around 12+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Diabetic Neuropathic Pain product details are provided in the report. Download the Diabetic Neuropathic Pain pipeline report to learn more about the emerging Diabetic Neuropathic Pain therapies [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Diabetic Neuropathic Pain Therapeutics Market include:

Key companies developing therapies for Diabetic Neuropathic Pain are - Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others.

Diabetic Neuropathic Pain Pipeline Analysis:

The Diabetic Neuropathic Pain pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Neuropathic Pain with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Neuropathic Pain Treatment.

*
Diabetic Neuropathic Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Diabetic Neuropathic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Neuropathic Pain market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Neuropathic Pain drugs and therapies [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Diabetic Neuropathic Pain Pipeline Market Drivers

*
Increasing prevalence of diabetes, unmet medical need, Aging population, Technological advancements, Regulatory incentives, are some of the important factors that are fueling the Diabetic Neuropathic Pain Market.

Diabetic Neuropathic Pain Pipeline Market Barriers

*
However, Complex pathophysiology, Heterogeneous patient population, Lack of predictive biomarkers, Safety concerns, Clinical trial design challenges, Reimbursement challenges and other factors are creating obstacles in the Diabetic Neuropathic Pain Market growth.

Scope of Diabetic Neuropathic Pain Pipeline Drug Insight

*
Coverage: Global

*
Key Diabetic Neuropathic Pain Companies: Rigshospitalet, CSPC Ouyi Pharmaceutical, Reata, Lexicon Pharmaceuticals, Jemincare, Eli Lilly and Company, GlaxoSmithKline, Apurano Pharmaceuticals, and others

*
Key Diabetic Neuropathic Pain Therapies: Incobotulinumtoxin-A 100 UNIT Injection, pregabalin sustained-release tablets, RTA 901, LX9211, JMKX000623, LY3556050, GSK3858279, Adezunap (AP707), and others

*
Diabetic Neuropathic Pain Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and Diabetic Neuropathic Pain emerging therapies

*
Diabetic Neuropathic Pain Market Dynamics: Diabetic Neuropathic Pain market drivers and Diabetic Neuropathic Pain market barriers

Request for Sample PDF Report for Diabetic Neuropathic Pain Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Diabetic Neuropathic Pain Report Introduction

2. Diabetic Neuropathic Pain Executive Summary

3. Diabetic Neuropathic Pain Overview

4. Diabetic Neuropathic Pain- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Neuropathic Pain Pipeline Therapeutics

6. Diabetic Neuropathic Pain Late Stage Products (Phase II/III)

7. Diabetic Neuropathic Pain Mid Stage Products (Phase II)

8. Diabetic Neuropathic Pain Early Stage Products (Phase I)

9. Diabetic Neuropathic Pain Preclinical Stage Products

10. Diabetic Neuropathic Pain Therapeutics Assessment

11. Diabetic Neuropathic Pain Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Neuropathic Pain Key Companies

14. Diabetic Neuropathic Pain Key Products

15. Diabetic Neuropathic Pain Unmet Needs

16 . Diabetic Neuropathic Pain Market Drivers and Barriers

17. Diabetic Neuropathic Pain Future Perspectives and Conclusion

18. Diabetic Neuropathic Pain Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-neuropathic-pain-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-by-delveinsight-helixmith-vertex-pharma-eisai-neurobo-pharma-astrazeneca]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.